Status; SplenectomyNCT02079064
Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy
A study testing Desflurane and Propofol in people with Status; Splenectomy, run by Theodor Bilharz Research Institute at 1 site in Egypt.
Trial summary
The aim of this prospective randomized study is to evaluate the perioperative effects of inhalational anesthesia (desflurane) and intravenous anesthesia (propofol) on hemostasis in patients undergoing splenectomy with liver cirrhosis guided by the new technology (ROTEM) and the traditional laboratory hemostatic… Read more about this study
- Who is it for?
- Ages 25 to 55 years
- Conditions the study is for
- Status; Splenectomy
- What is being tested?
- Desflurane and Propofol
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- Jan 2014to Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patient ASA physical status II and III.
- Age between 22-55 years.
- Child A suffering from pancytopenia.
- Type of surgery: splenectomy
Who cannot join
- Patients using oral anticoagulants
- Patients using antithrombotic drugs
- Patients using non steroidal anti-inflammatory drugs
- Patients using oral contraceptives
- Age less than 25 or more than 55 years
- Obese patients (body mass index >35 kg m-2)
- Pregnancy and lactation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis.
The aim of this prospective randomized study is to evaluate the perioperative effects of inhalational anesthesia (desflurane) and intravenous anesthesia (propofol) on hemostasis in patients undergoing splenectomy with liver cirrhosis guided by the new technology (ROTEM) and the traditional laboratory hemostatic markers.
Read the detailed description
After obtaining approval from the Institutional Research Ethics Committee and informed written consent, thirty adult patients aged 25- 55 years of either sex, American Society of Anesthesiologists (ASA) class II- III (Child A) suffering from cytopenia scheduled for elective splenectomy will be recruited. Pancytopenia is defined as anemia (hemoglobin < 13.5 g/dL-male; <12 g/dL-female); leucopenia (total leukocyte count < 4,000/mm3) and thrombocytopenia (platelet count < 150,000/mm3). Child B and C, Hb < 10 g/dL platelet count < 50,000/mm3, White Blood Cells (WBCs) < 2,000/mm3, prothrombin time [PT] > 16 s and INR > 1.7, extremes of age, obese patients (body mass index >35 kg m-2), and those using oral anticoagulants, other antithrombotic drugs, or oral contraceptives, will be excluded from the study.
All patients will be premedicated with 0.05 mg kg-1 i.v midazolam half an hour before operation. In the operating room, continuous pulse oximetry, electrocardiogram, non-invasive arterial blood pressure, PECO2, end-tidal anesthetic agent, neuromuscular monitoring, core temperature (Infinity Kappa, Dräger, Lübeck, Germany) and hourly urine output will be monitored throughout the operation. Depth of anesthesia will be monitored by using Bispectral index (BIS). All IV fluids will be warmed, and a warm air blanket (Bair Hugger) will be applied to every patient.
Thirty eligible patients will be allocated randomly to one of two equal groups (15 patients each) according to a computer generated randomization list: group D; maintenance of anesthesia with inhaled desflurane at 1 minimum alveolar concentration (MAC); group P, maintenance of anesthesia with target-controlled infusion (TCI) propofol with a target plasma concentration of propofol between 2 and 5 µg ml-1. The concentration of volatile anesthetics or the rate of infusion of injected anesthetics will be titrated to maintain the BIS numerical value between 40-50.
Anesthesia will be induced in both groups using i.v. fentanyl 1.5- 2 µg kg-1 and propofol 2- 2.5 mg kg-1. Atracurium 0.5 mg kg-1 will be administered for neuromuscular block and continued according to the response to train-of-four peripheral nerve stimulation. After intubation, patients will be mechanically ventilated with 30% oxygen in air throughout surgery using a low flow system (1L min-1) to adjust an end-tidal carbon dioxide (PECO2) between 30- 35 mmHg. Acetated Ringer's solution will be given as a preload and maintenance at a rate of 5-7 ml kg-1 h-1. Patients' systolic arterial pressures will be maintained at 100 mmHg or 70% of the preoperative value, whichever is higher. Hypotension will be treated with i.v. crystalloid fluid loading or intravenous boluses of ephedrine as appropriate. No colloid transfusion will be allowed. Transfusions of red blood cells will be used to maintain hemoglobin levels equal to or above 8 g dl-1. Platelets or fresh frozen plasma will be infused only when indicated by ROTEM. At the end of surgery, neuromuscular blockade will be antagonized with 0.05 mg kg-1 neostigmine and 0.02 mg kg-1 atropine. Postoperative analgesia was provided by intravenous infusion of 1 gm acetaminophen and IV meperidine 1 mg kg-1 every 12 hours. Patients are given an anti-emetic ondansetron 4 mg postoperatively.
Blood Sampling:
Five blood samples will be collected; before operation, after ligation of splenic artery, immediate post-operative, 24 hours and three days after the operation. Each time, five ml of venous blood will be collected and assessment of the following parameters will be performed:
Complete blood picture:
- Hemoglobin Concentration (by electronic cell counter).
- Hematocrit (by electronic cell counter).
- Platelet count (by electronic cell counter).
- Red blood cells (by electronic cell counter).
- White blood cells (by electronic cell counter).
Screening hemostatic tests:
- Prothrombin Time (PT) (by conventional method).
- International Normalized Ratio (INR) (by conventional method).
- Partial Thromboplastin Time (PTT) (by conventional method).
Specific hemostatic tests:
- Soluble platelet selectin (sP-selectin) [enzyme-linked immunosorbent assay (ELISA)].
- Fibrinogen level (coagulation method).
- D-dimer level (ELIZA).
At each sample time (0.3 ml blood) will be taken for measuring the following ROTEM variables:
- The time until initial fibrin formation (clotting time CT).
- The kinetics of fibrin formation and clot development (clot formation time (CFT) and α- angle).
- The ultimate strength and stability of the fibrin clot (maximum clot firmness MCF).
- Clot lysis (fibrinolysis). The previous parameters provide information about platelet activation, fibrin formation and clot retraction (all stages of the developing and resolving clot). Blood samples are activated extrinsically (by tissue factor) and intrinsically (by contact activator) via commercially available tests. Furthermore, fibrinogen levels will be assessed by measuring clot strength (MCF) in the presence of platelet inhibition (e.g., fib-TEM). This modified MCF represents the fibrin clot that developed in the absence of any platelets, i.e., the functional fibrinogen [6].
Routine laboratory tests:
- Serum creatinine.
- Alanine aminotransferase (ALT),aspartate aminotransferase (AST), albumin, bilirubin.
Routine investigations will be performed pre-, post-operative and on the third day.
Follow up of each patient will be done at out-patients clinic after one month to have thorough clinical examination, liver and kidney function tests, Child's Turcotte Pugh (CTP) score assessment, laboratory hematological tests and ROTEM assessment. This is important to assess post-operative complications, efficacy of splenectomy in improving cytopenia, and the influence of splenectomy on the natural course of disease.
Statistical Analysis:
No previous study was conducted to assess the effects of anesthetic agents on hemostasis during splenectomy with liver cirrhosis guided by ROTEM. Thus the calculation of the sample size is difficult and also the reagents required for ROTEM are expensive so we designed this thesis to be a pilot study. A sample size was chosen to be 15 patients in each group. Comparison between the two groups will be performed using Mann-Whitney test, while comparison within each group will be performed using Wilcoxon sign rank test. Comparison between repeated measures in both groups was performed using ANOVA. The data are considered significant if p values are ≤ 0.05. Statistical analysis will be performed with the aid of the Statistical Package for the Social Sciences (SPSS) computer program, version 12 windows (IBM, USA).
.
- Conditions
- Status; Splenectomy
- Being tested
- Desflurane, Propofol
- Keywords
- Splenectomy, Desflurane, Propofol, TCI, ROTEM
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DesfluraneDrug
Also called Suprane
Inhalational anesthetic
PropofolDrug
Also called Diprivan
Intravenous anesthetic that can be given by continuous infusion
| Study group | Role | What they receive |
|---|---|---|
| Desflurane | Experimental | Desflurane at 1 MAC and Receives: Drug: Desflurane |
| propofol | Experimental | propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1 Receives: Drug: Propofol |
What is being measured
The primary outcome is the main question the study is designed to answer.
maximum clot firmness (MCF)
Ultimate strength and stability of the fibrin clot measured by ROTEM.
Measured: Up to 1 month
Secondary outcomes (9)
clotting time CT
The time until initial fibrin formation measured by ROTEM
Measured: Up to 1 month
clot formation time; CFT
The kinetics of fibrin formation and clot development measured by ROTEM
Measured: Up to 1 month
D dimer
Indication of coagulation and fibrinolysis
Measured: Up to 1 month
Platelet count
Ability of clot formation
Measured: Up to 1 month
Prothrombin Time
measures of the extrinsic pathway of coagulation
Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
International Normalized Ratio (INR)
measures of the extrinsic pathway of coagulation
Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
sP-selectin
Acts as a receptor that supports binding of leukocytes to activated platelets and endothelium.
Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
Fibrinogen Level
A soluble plasma glycoprotein, that is converted by thrombin into fibrin during blood clot formation
Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
D-Dimer
A fibrin degradation product (or FDP) present in the blood after a blood clot is degraded by fibrinolysis
Measured: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2014 (estimated)
- Study startJan 2014
- Primary completionJun 2017
- Study completionJul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Status; SplenectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Theodor Bilharz Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yasser Mostafa Samhan, Theodor Bilharz Research Institute
- Investigators
- Gehan G El-Fandy, M.D., Study chair, Theodor Bilharz Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02079064
- Sponsor's protocol ID
- Anesthesia 98T
- Status last verified
- Oct 2016
- First submitted
- 27 Feb 2014
- Last updated
- 11 Oct 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006 Dec 28;12(48):7725-36. doi: 10.3748/wjg.v12.i48.7725.
PubMed 17203512Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci. 2003 Sep;326(3):111-6. doi: 10.1097/00000441-200309000-00001.
PubMed 14501224
Study at a glance
From the registry record, last updated by the sponsor on 11 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis.
- ClinicalTrials.gov ID
- NCT02079064
- Acronym / sponsor ID
- Anesthesia 98T
- Conditions
- Status; Splenectomy
- Keywords
- Splenectomy, Desflurane, Propofol, TCI, ROTEM
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Theodor Bilharz Research InstituteUniversity, hospital or other
- Study start
- Jan 2014
- Primary completion
- Jun 2017 (actual)
- Study completion
- Jul 2017 (actual)
- First posted
- 5 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this prospective randomized study is to evaluate the perioperative effects of inhalational anesthesia (desflurane) and intravenous anesthesia (propofol) on hemostasis in patients undergoing splenectomy with liver cirrhosis guided by the new technology (ROTEM) and the traditional laboratory hemostatic markers.
Detailed description
After obtaining approval from the Institutional Research Ethics Committee and informed written consent, thirty adult patients aged 25- 55 years of either sex, American Society of Anesthesiologists (ASA) class II- III (Child A) suffering from cytopenia scheduled for elective splenectomy will be recruited. Pancytopenia is defined as anemia (hemoglobin < 13.5 g/dL-male; <12 g/dL-female); leucopenia (total leukocyte count < 4,000/mm3) and thrombocytopenia (platelet count < 150,000/mm3). Child B and C, Hb < 10 g/dL platelet count < 50,000/mm3, White Blood Cells (WBCs) < 2,000/mm3, prothrombin time [PT] > 16 s and INR > 1.7, extremes of age, obese patients (body mass index >35 kg m-2), and those using oral anticoagulants, other antithrombotic drugs, or oral contraceptives, will be excluded from the study.
All patients will be premedicated with 0.05 mg kg-1 i.v midazolam half an hour before operation. In the operating room, continuous pulse oximetry, electrocardiogram, non-invasive arterial blood pressure, PECO2, end-tidal anesthetic agent, neuromuscular monitoring, core temperature (Infinity Kappa, Dräger, Lübeck, Germany) and hourly urine output will be monitored throughout the operation. Depth of anesthesia will be monitored by using Bispectral index (BIS). All IV fluids will be warmed, and a warm air blanket (Bair Hugger) will be applied to every patient.
Thirty eligible patients will be allocated randomly to one of two equal groups (15 patients each) according to a computer generated randomization list: group D; maintenance of anesthesia with inhaled desflurane at 1 minimum alveolar concentration (MAC); group P, maintenance of anesthesia with target-controlled infusion (TCI) propofol with a target plasma concentration of propofol between 2 and 5 µg ml-1. The concentration of volatile anesthetics or the rate of infusion of injected anesthetics will be titrated to maintain the BIS numerical value between 40-50.
Anesthesia will be induced in both groups using i.v. fentanyl 1.5- 2 µg kg-1 and propofol 2- 2.5 mg kg-1. Atracurium 0.5 mg kg-1 will be administered for neuromuscular block and continued according to the response to train-of-four peripheral nerve stimulation. After intubation, patients will be mechanically ventilated with 30% oxygen in air throughout surgery using a low flow system (1L min-1) to adjust an end-tidal carbon dioxide (PECO2) between 30- 35 mmHg. Acetated Ringer's solution will be given as a preload and maintenance at a rate of 5-7 ml kg-1 h-1. Patients' systolic arterial pressures will be maintained at 100 mmHg or 70% of the preoperative value, whichever is higher. Hypotension will be treated with i.v. crystalloid fluid loading or intravenous boluses of ephedrine as appropriate. No colloid transfusion will be allowed. Transfusions of red blood cells will be used to maintain hemoglobin levels equal to or above 8 g dl-1. Platelets or fresh frozen plasma will be infused only when indicated by ROTEM. At the end of surgery, neuromuscular blockade will be antagonized with 0.05 mg kg-1 neostigmine and 0.02 mg kg-1 atropine. Postoperative analgesia was provided by intravenous infusion of 1 gm acetaminophen and IV meperidine 1 mg kg-1 every 12 hours. Patients are given an anti-emetic ondansetron 4 mg postoperatively.
Blood Sampling:
Five blood samples will be collected; before operation, after ligation of splenic artery, immediate post-operative, 24 hours and three days after the operation. Each time, five ml of venous blood will be collected and assessment of the following parameters will be performed:
Complete blood picture:
- Hemoglobin Concentration (by electronic cell counter).
- Hematocrit (by electronic cell counter).
- Platelet count (by electronic cell counter).
- Red blood cells (by electronic cell counter).
- White blood cells (by electronic cell counter).
Screening hemostatic tests:
- Prothrombin Time (PT) (by conventional method).
- International Normalized Ratio (INR) (by conventional method).
- Partial Thromboplastin Time (PTT) (by conventional method).
Specific hemostatic tests:
- Soluble platelet selectin (sP-selectin) [enzyme-linked immunosorbent assay (ELISA)].
- Fibrinogen level (coagulation method).
- D-dimer level (ELIZA).
At each sample time (0.3 ml blood) will be taken for measuring the following ROTEM variables:
- The time until initial fibrin formation (clotting time CT).
- The kinetics of fibrin formation and clot development (clot formation time (CFT) and α- angle).
- The ultimate strength and stability of the fibrin clot (maximum clot firmness MCF).
- Clot lysis (fibrinolysis). The previous parameters provide information about platelet activation, fibrin formation and clot retraction (all stages of the developing and resolving clot). Blood samples are activated extrinsically (by tissue factor) and intrinsically (by contact activator) via commercially available tests. Furthermore, fibrinogen levels will be assessed by measuring clot strength (MCF) in the presence of platelet inhibition (e.g., fib-TEM). This modified MCF represents the fibrin clot that developed in the absence of any platelets, i.e., the functional fibrinogen [6].
Routine laboratory tests:
- Serum creatinine.
- Alanine aminotransferase (ALT),aspartate aminotransferase (AST), albumin, bilirubin.
Routine investigations will be performed pre-, post-operative and on the third day.
Follow up of each patient will be done at out-patients clinic after one month to have thorough clinical examination, liver and kidney function tests, Child's Turcotte Pugh (CTP) score assessment, laboratory hematological tests and ROTEM assessment. This is important to assess post-operative complications, efficacy of splenectomy in improving cytopenia, and the influence of splenectomy on the natural course of disease.
Statistical Analysis:
No previous study was conducted to assess the effects of anesthetic agents on hemostasis during splenectomy with liver cirrhosis guided by ROTEM. Thus the calculation of the sample size is difficult and also the reagents required for ROTEM are expensive so we designed this thesis to be a pilot study. A sample size was chosen to be 15 patients in each group. Comparison between the two groups will be performed using Mann-Whitney test, while comparison within each group will be performed using Wilcoxon sign rank test. Comparison between repeated measures in both groups was performed using ANOVA. The data are considered significant if p values are ≤ 0.05. Statistical analysis will be performed with the aid of the Statistical Package for the Social Sciences (SPSS) computer program, version 12 windows (IBM, USA).
.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Desflurane | Experimental | Drug: DesfluraneDesflurane at 1 MAC and |
| propofol | Experimental | Drug: Propofolpropofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1 |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Patient ASA physical status II and III.
- Age between 22-55 years.
- Child A suffering from pancytopenia.
- Type of surgery: splenectomy
Key exclusion criteria (7 listed)
- Patients using oral anticoagulants
- Patients using antithrombotic drugs
- Patients using non steroidal anti-inflammatory drugs
- Patients using oral contraceptives
- Age less than 25 or more than 55 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DesfluraneAlso: SupraneInhalational anesthetic | Drug | Desflurane |
| PropofolAlso: DiprivanIntravenous anesthetic that can be given by continuous infusion | Drug | propofol |
Primary outcome
maximum clot firmness (MCF)
Time frame: Up to 1 month
Ultimate strength and stability of the fibrin clot measured by ROTEM.
9 secondary outcomes
clotting time CT
Time frame: Up to 1 month
clot formation time; CFT
Time frame: Up to 1 month
D dimer
Time frame: Up to 1 month
Platelet count
Time frame: Up to 1 month
Prothrombin Time
Time frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
International Normalized Ratio (INR)
Time frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
sP-selectin
Time frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
Fibrinogen Level
Time frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
D-Dimer
Time frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Oct 2017.
- Results publication: PubMed 17203512Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006 Dec 28;12(48):7725-36. doi: 10.3748/wjg.v12.i48.7725.
- Results publication: PubMed 14501224Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci. 2003 Sep;326(3):111-6. doi: 10.1097/00000441-200309000-00001.
- Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 12(48): 7725-36Link provided by the sponsor.
- Liangpunsakul S, Sithat M, Ulmer B, Chalasani. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sciences 2003; 326: 111-16.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Status; Splenectomy
Not yet recruitingObservational study
Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Cirrhosis, Splenectomy; Status
Not yet recruitingObservational study
Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Cirrhosis, Liver, Splenectomy; Status
Not yet recruitingObservational study
Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Cirrhosis, Liver, Splenectomy; Status
Not yet recruitingObservational study
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Cirrhosis, Splenectomy; Status
RecruitingObservational study
Development of an Italian Questionnaire for Splenectomized Patients Using a Delphi Consensus Method
Splenectomy; Status, Asplenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gehan G El-Fandy, M.D. study chair
Theodor Bilharz Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Desflurane and Propofol in people with Status; Splenectomy, run by Theodor Bilharz Research Institute at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
maximum clot firmness (MCF) (time frame: Up to 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02079064, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2017.